Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVENT AGITATION II
NCT05091242Phase 3Recruiting
- Sponsor
- Rigshospitalet
- Start
- Oct 2021
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial in emergence delirium (ED) comparing Clonidine with Placebo (2 arms). Primary endpoints: Incidence of emergence agitation during stay in postanaesthetic care unit (PACU) up to 4 hours, Compartmental clearance for pharmacokinetic profiling and 2 more. Started Oct 2021; status: recruiting.
02
Drugs
clonidine
03
Conditions
emergence delirium (ED)
Beyond the preview
Go deeper on NCT05091242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091242.